Cogent Biosciences, Inc. COGT Proceeds From Issuance Under At The Market Offering
Proceeds From Issuance Under At The Market Offering at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept cogt:ProceedsFromIssuanceUnderAtTheMarketOffering.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s proceeds from issuance under at the market offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s proceeds from issuance under at the market offering?
- Cogent Biosciences, Inc. (COGT) reported proceeds from issuance under at the market offering of $45.71M in Q1 2026.
- How has Cogent Biosciences, Inc.'s proceeds from issuance under at the market offering changed year-over-year?
- Cogent Biosciences, Inc.'s proceeds from issuance under at the market offering increased by 88.5% year-over-year, from $24.25M to $45.71M.
- What is the long-term trend for Cogent Biosciences, Inc.'s proceeds from issuance under at the market offering?
- Over 3 years (2021 to 2024), Cogent Biosciences, Inc.'s proceeds from issuance under at the market offering has grown at a -100.0% compound annual growth rate (CAGR), from $38.01M to $0.
- What does proceeds from issuance under at the market offering mean?
- Measures the cash proceeds generated from selling shares of common stock directly into the open market at prevailing market prices. This flexible financing tool allows companies to raise capital incrementally without the need for a traditional underwritten offering. It is a key indicator of the company's ability to access equity markets to fund ongoing research and development activities.